Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.34 |
| ▸ | MICA | Q29983 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358340 | 0.95 | GAA (0.38) | HTR2CPDK2GAACYP3A4AKR1C3 | |
| SCHEMBL1360377 | 0.93 | CHEK1 (0.34) | HTR2CPDK2GAACHEK1CYP3A4 | |
| SCHEMBL1360466 | 0.93 | CHEK1 (0.37) | HTR2CGAACHEK1CYP3A4AKR1C3 | |
| SCHEMBL3144840 | 0.93 | CHEK1 (0.37) | HTR2CGAACHEK1CYP3A4AKR1C3 | |
| SCHEMBL1359531 | 0.90 | KCNH2 (0.33) | HTR2CCHEK1CYP3A4 | |
| SCHEMBL1359618 | 0.89 | CHEK1 (0.42) | PDK2GAACHEK1CYP3A4 | |
| SCHEMBL12138497 | 0.89 | GAA (0.36) | GAACHEK1CYP3A4AKR1C3 | |
| SCHEMBL1359541 | 0.89 | CYP3A4 (0.34) | HTR2CCHEK1CYP3A4 | |
| SCHEMBL1359499 | 0.89 | CYP3A4 (0.37) | HTR2CCHEK1CYP3A4RORC | |
| SCHEMBL1358011 | 0.89 | CYP3A4 (0.37) | HTR2CCHEK1CYP3A4RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067442-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-29 | — | — | US | claimed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, POLR2A, HCCS | HTR2C 1771/4885PDK2 2000/4885GAA 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.